CLC bio implements specialized antibody engineering and selection module for Crucell

Today CLC bio announced the completion and final implementation of a specialized antibody engineering and selection module for Crucell, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, that integrates with CLC bio's bioinformatics platform. The specialized module is designed to optimize the end-to-end workflow and analysis pipeline when working with a large number of antibodies during the process of developing new therapies for various diseases amongst which infectious diseases and cancer

"When investigating the diversity and complexity of antibody repertories, speed and quality are essential. The faster we can go through our bioinformatics workflow and identify antibodies of interest, the earlier we can move to the next phases in our research and development, which is of course extremely important for us" says Innovation & Discovery Scientist at Crucell, David Zuijdgeest, and continues, "CLC bio has fully integrated the workflow by automating all the steps in the downstream bioinformatics analysis process. Not only has this accelerated the research process tremendously by eliminating tedious and complicated manual procedures, but it also provides a high quality and robust workflow."

Director of Consulting Services at CLC bio, Dr. Jannick D. Bendtsen, continues, "This intricate solution which we have customized for Crucell stresses the flexibility and stability of our bioinformatics platform. And apart from a commercial point of view, it's also a personal pleasure for us to assist Crucell in discovering and developing products that combat infectious diseases, which ultimately helps saving lives and preventing illness around the world."